Lipoprotein(a) and Risk of Treated Ventricular Arrhythmias in Heart Failure

This cross-sectional study investigates the association between lipoprotein(a) levels and risk of ventricular arrhythmias among patients with heart failure with reduced ejection fraction receiving implantable cardioverter-defibrillator therapy.

Corresponding Author: Ramzi Ibrahim, MD, Department of Cardiovascular Medicine, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259 (ibrahim.ramzi@mayo.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.